[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Telios Pharma, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,60],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100609886","phase-2-evaluation-of-tl-925-for-the-treatment-of-seasonal-allergic-conjunctivitis-100609886",false,"NCT07220408","Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis","A Single Center, Randomized, Double-masked, Vehicle Controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Seasonal Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model","Inclusion Criteria:\n\n* Individuals aged 18 years or older\n* Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.\n* Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.\n* Calculated best-corrected visual activity\n* Positive bilateral CAC reaction\n\nExclusion Criteria:\n\n* Any systemic or ocular disease currently producing ocular redness and\u002For ocular discomfort, or that may interfere with the conduct of the study.\n* Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months\n* Any ongoing ocular infection (bacterial, viral or fungal)","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.\n\nThe study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.",[26],"Allergic Conjunctivitis","RECRUITING","2025-11-22",{"date":30,"type":31},"2025-11-25","ACTUAL",{"date":33,"type":31},"2025-10-23",{"date":35,"type":20},"2026-02",{"name":37,"class":38},"Telios Pharma, Inc.","INDUSTRY",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":39},"100568841","phase-2-evaluation-of-tl-925-for-the-treatment-of-allergic-conjunctivitis-100568841","NCT06686472","Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis","A Single-Center, Randomized, Double-masked, Vehicle-controlled Phase 2 Study Evaluating the Safety and Efficacy of TL-925 Ophthalmic Emulsion 0.1% Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model","Inclusion Criteria:\n\n* Individuals aged 18 years or older\n* Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.\n* Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.\n* Calculated best-corrected visual activity of 0.7 LogMAR or better\n* Positive bilateral CAC reaction\n\nExclusion Criteria:\n\n* Any systemic or ocular disease currently producing ocular redness and\u002For ocular discomfort, or that may interfere with the conduct of the study.\n* Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months\n* Any ongoing ocular infection (bacterial, viral or fungal)",{"count":48,"type":20},66,[23],"In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally.\n\nThe study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.",[26],"2024-11-11",{"date":54,"type":31},"2024-11-13",{"date":56,"type":31},"2024-10-03",{"date":58,"type":20},"2024-12-10",{"name":37,"class":38},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":71,"conditions":72,"keywords":77,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100460813","phase-1-study-of-tl-895-combined-with-ruxolitinib-in-jaki-treatment-nave-mf-subjects-and-subjects-with-mf-who-have-a-suboptimal-response-to-ruxolitinib-100460813","NCT05280509","Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib","An Open-Label, Multicenter, Phase 1b\u002F2 Study of the Safety and Efficacy of TL-895 Combined With Ruxolitinib in Janus-associated Kinase Inhibitor (JAKi) Treatment-Naïve Myelofibrosis (MF) Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib","Inclusion Criteria:\n\nSubjects with suboptimal response to ruxolitinib:\n\n* Treatment with at a stable dose of ruxolitinib prior to study entry\n* Subjects ≥ 18 years of age and able to provide informed consent.\n* Confirmed diagnosis of PMF, post-PV MF, or post-ET MF, as assessed by treating physician according to the World Health Organization (WHO) criteria\n* High-risk, intermediate-2 risk, or intermediate-1 risk, defined by Dynamic International Prognostic System (DIPSS)\n* Palpable spleen measuring ≥ 5 cm below the left lower coastal margin (LLCM) or spleen volume of ≥ 450 cm3 by MRI or CT scan assessment\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Adequate hematological, hepatic, \\& renal function.\n\nExclusion Criteria:\n\nTreatment-naive subjects:\n\n* Prior treatment with any JAKi\n\nSubjects with suboptimal response to ruxolitinib:\n\n* Documented disease progression while on ruxolitinib treatment\n\nAll subjects:\n\n* Prior splenectomy or splenic irradiation within 24 weeks prior to first dose of study treatment\n* Prior treatment with a BTK or BMX inhibitor",{"count":68,"type":20},70,[70,23],"PHASE1","This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.",[73,74,75,76],"Myelofibrosis","Primary Myelofibrosis","Post-PV MF","Post-ET Myelofibrosis",[73],"2023-02-16",{"date":80,"type":31},"2023-02-21",{"date":82,"type":31},"2022-06-09",{"date":84,"type":20},"2027-04",{"name":37,"class":38},19,""]